4.7 Article

A Clinical Workflow for Cost-Saving High-Rate Diagnosis of Genetic Kidney Diseases

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 34, Issue 4, Pages 706-720

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.0000000000000076

Keywords

whole-exome sequencing; reverse phenotyping; genetic renal disease; chronic kidney disease; cost analysis; workflow; cost

Ask authors/readers for more resources

WES can increase the diagnostic rate of genetic kidney disorders. This study identified several clinical criteria that were predictive of genetic diagnosis, and applied a multistep workflow incorporating WES to successfully diagnose a high percentage of patients.
Background Whole-exome sequencing (WES) increases the diagnostic rate of genetic kidney disorders, but accessibility, interpretation of results, and costs limit use in daily practice.Methods Univariable analysis of a historical cohort of 392 patients who underwent WES for kidney diseases showed that resistance to treatments, familial history of kidney disease, extrarenal involvement, congenital abnormalities of the kidney and urinary tract and CKD stage $G2, two or more cysts per kidney on ultrasound, persistent hyper echoic kidneys or nephrocalcinosis on ultrasound, and persistent metabolic abnormalities were most predictive for genetic diagnosis. We prospectively applied these criteria to select patients in a network of nephrology centers, followed by centralized genetic diagnosis by WES, reverse phenotyping, and multidisciplinary board discussion.Results We applied this multistep workflow to 476 patients with eight clinical categories (podocytopathies, collagenopathies, CKD of unknown origin, tubulopathies, ciliopathies, congenital anomalies of the kidney and urinary tract, syndromic CKD, metabolic kidney disorders), obtaining genetic diagnosis for 319 of 476 patients (67.0%) (95% in 21 patients with disease onset during the fetal period or at birth, 64% in 298 pediatric patients, and 70% in 156 adult patients). The suspected clinical diagnosis was confirmed in 48% of the 476 patients and modified in 19%. A modeled cost analysis showed that application of this workflow saved 20% of costs per patient when performed at the beginning of the diagnostic process. Real cost analysis of 66 patients randomly selected from all categories showed actual cost reduction of 41%. Conclusions A diagnostic workflow for genetic kidney diseases that includes WES is cost-saving, especially if implemented early, and is feasible in a real-world setting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available